Lars Klareskog

from Wikipedia, the free encyclopedia
Klareskog (2013)

Lars Klareskog (* 1945 ) is a Swedish physician (immunologist, rheumatologist) known for researching the genetics of autoimmune diseases such as rheumatoid arthritis (RA).

Klareskog received his medical degree from Uppsala University in 1974 and received his doctorate there in 1978 (On the structure, function and tissue distribution of HLA-DR and Ia antigens). From 1990 to 1993 he held the chair of clinical immunology at Uppsala University. He then held the chair for rheumatology at the Karolinska Institute and the Karolinska Clinic until 2012 and was head of the Rheumatological Clinic and Research Group. Since 2008 he has also been director of the Center for Molecular Medicine there.

In the mid-2000s, he and his team discovered a significantly higher susceptibility to rheumatoid arthritis with a genetic disposition ( HLA risk genes) and ACPA -positive patients who were also smokers. According to Klareskog, smoking leads to citrullination of proteins (conversion of the amino acid arginine into citrulline , e.g. mutated citrullinated vimentin , MCV), to which the ACPA antibodies reacted.

He was visiting professor and visiting scholar at Harvard Medical School, Imperial College London (Kennedy Institute of Rheumatology), the Hospital of Special Surgery at Cornell University, in Seattle, Leeds and Denver (University of Colorado).

In 2013 he received the Crafoord Prize with Robert J. Winchester and Peter K. Gregersen for polyarthritis research.

From 1995 to 2012 he was a member of the Nobel Committee.

Fonts

  • A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope) -restricted immune reactions to autoantigens modified by citrullination . In: Arthritis & Rheumatism , Volume 54, January 2006, pp. 38-46.
  • with H. Källberg u. a. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis , American J. Hum. Genetics, Vol. 80, 2007, pp. 867-875
  • with EF Remmers u. a. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus . In: New England Journal of Medicine , Volume 357, 2007, pp. 977-986.
  • with J. Rönnelid, K. Lundberg and others: Immunity to citrullinated proteins in rheumatoid arthritis . In: Annual Review of Immunology , Volume 26, 2008, pp. 651-675.
  • with others: Rheumatoid arthritis (seminar) . In: The Lancet , Volume 373, 2009 pp. 659-672
  • with H. Mahdi a. a .: Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis . In: Nature Genetics , Volume 41, 2009, pp. 1319-1324
  • with S. Saevarsdottir and others: Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and TNF inhibitors. Observations from the EIRA cohort and the Swedish Rheumatology Register . In: Arthritis & Rheumatism , January 2011.
  • L Mathsson, M Mullazehi, MC Wick, O Sjöberg, R van Vollenhoven, L Klareskog et al .: Antibodies against citrullinated vimentin in rheumatoid arthritis: Higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides . In: Arthritis Rheum , 2007, 58 (1), pp. 36-45

Web links

Individual evidence

  1. ↑ Tests for autoantibodies against MCV are used for the early diagnosis of RA
  2. ^ Announcement by the Crafoord Foundation
personal data
SURNAME Klareskog, Lars
BRIEF DESCRIPTION Swedish medic
DATE OF BIRTH 1945